skip navigation links
National Cancer Institute
EVS Logo NCI Term Browser Enterprise Vocabulary Services
Terminologies Value Sets Mappings
Version: 17.06d (Release date: 2017-06-26)
SearchBox Top
SearchBox Bottom
Rilimogene Galvacirepvec (Code C38681)

Terms & Properties Synonym Details Relationships Mapping View All  
Terms & Properties

Preferred Name: Rilimogene Galvacirepvec

Definition: A vaccine formulation consisting of recombinant vaccinia virus encoding prostate specific antigen (PSA) and recombinant vaccinia virus encoding three co-stimulatory molecule transgenes B7.1, ICAM-1, and LFA-3 (TRICOM). Vaccination with PSA in combination with TRICOM may enhance antigen presentation, resulting in the augmentation of a cytotoxic T cell (CTL) immune response against tumor cells expressing PSA.

Display Name: Rilimogene Galvacirepvec

Label: Rilimogene Galvacirepvec

NCI Thesaurus Code: C38681 (Search for linked caDSR metadata)  (search value sets)

NCI Metathesaurus Link: C1519903  (see NCI Metathesaurus info)

Synonyms & Abbreviations: (see Synonym Details)
Recombinant Vaccinia-PSA(L155)-TRICOM Vaccine
Recombinant Vaccinia-PSA(L155)/TRICOM
Recombinant Vaccinia-PSA(L155)/TRICOM Vaccine
Rilimogene Galvacirepvec
rVaccinia-Prostate-Specific Antigen/TRICOM Vaccine
rVaccinia-PSA(L155)-TRICOM Vaccine

External Source Codes: 
CAS Registry Number 1225283-43-1 (see NLM ChemIDplus info)
NSC Code 717170 (see NCI DTP info)
PDQ Closed Trial Search ID 305934
PDQ Open Trial Search ID 305934 (check for NCI PDQ open clinical trial info)
UMLS CUI C1519903

Other Properties:
     Name Value (qualifiers indented underneath)
code C38681
Contributing_Source CTRP
Legacy_Concept_Name Vaccinia-PSA-TRICOM_Vaccine
Semantic_Type Immunologic Factor
Semantic_Type Pharmacologic Substance
Semantic_Type Virus

Additional Concept Data: 
Defined Fully by Roles: No  


Mainbox Bottom